128 related articles for article (PubMed ID: 10537437)
1. Costs of peripheral blood progenitor cell transplantation using whole blood mobilised by filgrastim as compared with autologous bone marrow transplantation in non-Hodgkin's lymphoma.
Uyl-de Groot CA; Ossenkoppele GJ; Buijt I; Huijgens PC
Pharmacoeconomics; 1999 Mar; 15(3):305-11. PubMed ID: 10537437
[TBL] [Abstract][Full Text] [Related]
2. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH
J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118
[TBL] [Abstract][Full Text] [Related]
3. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients.
Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Demuynck HM; Link H; Zander A; Barge A
Lancet; 1996 Feb; 347(8998):353-7. PubMed ID: 8598700
[TBL] [Abstract][Full Text] [Related]
4. Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim); a less costly alternative to autologous bone marrow transplantation.
Uyl-de Groot CA; Richel DJ; Rutten FF
Eur J Cancer; 1994; 30A(11):1631-5. PubMed ID: 7530471
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients.
Damiani D; Fanin R; Silvestri F; Grimaz S; Infanti L; Geromin A; Cerno M; Michieli M; Rinaldi C; Savignano C; Trani G; Fiacchini M; Baccarani M
Blood; 1997 Jul; 90(1):36-42. PubMed ID: 9207435
[TBL] [Abstract][Full Text] [Related]
6. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
Stahel RA; Jost LM; Cerny T; Pichert G; Honegger H; Tobler A; Jacky E; Fey M; Platzer E
J Clin Oncol; 1994 Sep; 12(9):1931-8. PubMed ID: 7521907
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of autologous bone marrow transplantation.
Lawless GD
Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S11-4. PubMed ID: 8846240
[TBL] [Abstract][Full Text] [Related]
8. Stem cell transplantations in patients with malignant lymphoma: costs in a Dutch university hospital in the period 1984-1995.
Uyl-de Groot CA; Ossenkoppele GJ; Buijt I; Huijgens PC
J Hematother Stem Cell Res; 1999 Dec; 8(6):619-25. PubMed ID: 10645769
[TBL] [Abstract][Full Text] [Related]
9. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. a prospective randomised trial.
van Agthoven M; Vellenga E; Fibbe WE; Kingma T; Uyl-de Groot CA
Eur J Cancer; 2001 Sep; 37(14):1781-9. PubMed ID: 11549432
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma.
Messori A; Bonistalli L; Costantini M; Alterini R
Bone Marrow Transplant; 1997 Feb; 19(3):275-81. PubMed ID: 9028558
[TBL] [Abstract][Full Text] [Related]
11. Cost analysis of autologous peripheral stem cell transplantation versus autologous bone marrow transplantation for patients with non Hodgkin's lymphoma and acute lymphoblastic leukaemia.
Jerjis S; Croockewit S; Muus P; Schaap N; Preijers F; de Witte T
Leuk Lymphoma; 1999 Dec; 36(1-2):33-43. PubMed ID: 10613448
[TBL] [Abstract][Full Text] [Related]
12. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.
Lemoli RM; Rosti G; Visani G; Gherlinzoni F; Miggiano MC; Fortuna A; Zinzani P; Tura S
J Clin Oncol; 1996 Nov; 14(11):3018-25. PubMed ID: 8918500
[TBL] [Abstract][Full Text] [Related]
13. The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma.
Uyl-de Groot CA; Ossenkoppele GJ; van Riet AA; Rutten FF
Eur J Cancer; 1994; 30A(4):457-9. PubMed ID: 7517149
[TBL] [Abstract][Full Text] [Related]
14. Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients.
Woronoff-Lemsi MC; Arveux P; Limat S; Deconinck E; Morel P; Cahn JY
Bone Marrow Transplant; 1997 Dec; 20(11):975-82. PubMed ID: 9422478
[TBL] [Abstract][Full Text] [Related]
15. Treatment of aggressive non-Hodgkin's lymphoma with chemotherapy in combination with filgrastim.
Schriber J
Drugs; 2002; 62 Suppl 1():33-46. PubMed ID: 12479593
[TBL] [Abstract][Full Text] [Related]
16. Administration of granulocyte colony-stimulating factor from day 7 after autologous bone marrow transplantation: effects on neutropenia and duration of hospitalization.
Moreau P; Le Tortorec S; Mahé B; Legros L; Milpied N; Harousseau JL
Nouv Rev Fr Hematol (1978); 1994 Dec; 36(6):455-8. PubMed ID: 7538659
[TBL] [Abstract][Full Text] [Related]
17. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
18. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Majolino I; Pearce R; Taghipour G; Goldstone AH
J Clin Oncol; 1997 Feb; 15(2):509-17. PubMed ID: 9053472
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recovery.
Ianotto JC; Ngo Sack F; Couturier MA; Tempescul A; Mugnier N; Delepine P; Guillerm G; Berthou C
Leuk Lymphoma; 2014 Jan; 55(1):74-7. PubMed ID: 23566160
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
